Other Events ·
Tiziana Life Sciences Ltd announced on June 25, 2026, that the final patient in its Phase 2a clinical trial has…
TLSATiziana Life Sciences Ltd
Tiziana Life Sciences Ltd announced on June 25, 2026, that the final patient in its Phase 2a clinical trial has received the first dose of intranasal foralumab for treating non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data results are anticipated in late Q3 or early Q4 of 2026. The company intends to present these findings at the 10th joint ACTRIMS and ECTRIMS meeting in Toronto, Canada, during October 2026. Tiziana Life Sciences is a biopharmaceutical company focused on developing novel therapies.